# Jan B. Vermorken

Source: https://onco.cc/people/jan-vermorken/  
OnCo record `jan-vermorken` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led EXTREME and TAX 323, which defined the chemotherapy standards for head and neck cancer for a decade.

## Summary

Jan Vermorken (Antwerp University Hospital) was principal investigator of EXTREME, which showed adding cetuximab to platinum-fluorouracil improves survival in recurrent or metastatic head and neck cancer and became the comparator arm for KEYNOTE-048, and of TAX 323, which established docetaxel-based induction chemotherapy. He also led early cisplatin-based trials in cervical cancer and has chaired EORTC head and neck research.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: head-and-neck; chemotherapy; eortc
- Role: Emeritus Professor of Oncology, Antwerp University Hospital
- Specialisms: Head and neck cancer; Chemotherapy; Anti-EGFR therapy; Cervical cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- institutions: [Antwerp University Hospital (UZA)](https://onco.cc/institutions/antwerp-university-hospital/)
- trials: [EXTREME](https://onco.cc/trials/extreme/)

---
JSON: https://onco.cc/api/v1/entities/jan-vermorken.json